Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;21(1):2516949.
doi: 10.1080/21645515.2025.2516949. Epub 2025 Jun 10.

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)

Ener Cagri Dinleyici  1 , Ergin Ciftci  2 , Ayper Somer  3 , Dilek Yilmaz  4 , Hasan Tezer  5
Affiliations
Review

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)

Ener Cagri Dinleyici et al. Hum Vaccin Immunother. 2025 Dec.

Abstract

Neisseria meningitidis (Nm) remains a major global health concern, causing invasive meningococcal disease (IMD) with significant morbidity and mortality. Despite vaccination efforts, Nm serogroup prevalence and antibiotic resistance continue to evolve, necessitating ongoing surveillance and novel immunization strategies. This review aims to assess the role of MenACWY-TT, a quadrivalent meningococcal conjugate vaccine, in IMD prevention by evaluating its immunogenicity, safety, and real-world effectiveness. The objectives include analyzing its advantages over existing vaccines, identifying gaps in long-term immunity data, and assessing its potential integration into National Immunization Programs (NIPs). MenACWY-TT has demonstrated strong immunogenicity, a favorable safety profile, and ease of administration with its liquid, non-adjuvanted formulation. Real-world studies show high vaccine effectiveness and herd protection benefits. However, further research is needed to evaluate long-term immunity and efficacy in high-risk populations.

Keywords: MenACWY; MenACWY-TT; MenQuadfi; Meningococcal vaccine; Neisseria meningitidis; invasive meningococcal disease prevention.

PubMed Disclaimer

Conflict of interest statement

ECD performs contact work for Eskisehir Osmangazi University funded by Glaxo Smith Kline, Pfizer, Merck Sharp&Dohme, and Sanofi. EC has acted in advisory board of Glaxo Smith Kleine, Merck Sharp&Dohme, Sanofi and Pfizer, and has received speaker honorarium from Glaxo Smith Kleine, Merck Sharp&Dohme, Sanofi and Pfizer. AS reports there is no competing interest to declare. DY has acted in advisory board of Sanofi, Glaxo Smith Kleine, Merck Sharp&Dohme, and Pfizer and has received speaker honorarium from Sanofi, Glaxo Smith Kleine, Merck Sharp&Dohme, and Pfizer. HT has acted in advisory board of Sanofi.

References

    1. Rouphael NG, Stephens DS.. Neisseria meningitidis: biology, microbiology, and epidemiology. Neisseria Meningitidis: Adv Met Protocol. 2012; 1–11. https://pubmed.ncbi.nlm.nih.gov/21993636/. - PMC - PubMed
    1. Schubert-Unkmeir A. Molecular mechanisms involved in the interaction of Neisseria meningitidis with cells of the human blood–cerebrospinal fluid barrier. Pathog Dis. 2017;75(2):ftx023. doi: 10.1093/femspd/ftx023. - DOI - PubMed
    1. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30:B3–B9. doi: 10.1016/j.vaccine.2011.12.062. - DOI - PubMed
    1. Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–783. doi: 10.1016/S1474-4422(12)70180-1. - DOI - PubMed
    1. Read RC. Neisseria meningitidis and meningococcal disease: recent discoveries and innovations. Curr Opin Infect Dis. 2019;32(6):601–608. doi: 10.1097/QCO.0000000000000606. - DOI - PubMed

MeSH terms

LinkOut - more resources